bladder cancer
Veracyte Bladder Cancer Test Receives Medicare Coverage
The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies.
OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence
Premium
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.
Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers
Researchers said that the score further may identify patients whose treatment resistance may be overcome with combination strategies targeting certain cells.
The Rehovot, Israel-based firm expects to soon receive marketing clearance from the US Food and Drug Administration for its methylation-based Bladder EpiCheck test.
Mar 18, 2021
May 19, 2020
Apr 6, 2020
Dec 11, 2019